Neuron23 (Series A and B)
Funding Details
- Awarder
- Inbox
- Date Award
- December 16, 2020
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $113,500,000
Company Info
- Founding Year
- 2018
- Company Description
- Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
- Market
- Genetically defined neurological and immunological diseases
- Location
- South San Francisco, California, USA
- Coinvestors
- Acorn Bioventures, Cowen Healthcare Investments, HBM Partners, Kleiner Perkins Caufield and Byers, Perceptive Advisors, Redmile Group, Surveyor Capital, Westlake Village BioPartners